PATENT CLAIM ANALYSIS

Application Number: 16100065
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "139100"]

Abstract:
Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Claim (Index 13):
The method of  claim 9 , wherein the infection is viral infection, bacterial infection, fungal infection or infection by a parasite.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 96.0
- Lexical Diversity: 2.27273
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15744737', '16100019', '16069144', '16069487', '15328232']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7886753352202435
- 35 USC 102 Novelty (BERT): 0.5720139826828583
- Combined Prediction Score: 0.767009199966505
- Mean Citation Score: 409.118768
- Max Citation Score: 508.21893
- Similarity Product: 361.96850946462393

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test